Radioisotope producer Nordion International has settled a disputewith a Canadian government agency that had stalled the constructionof nuclear reactors dedicated to producing molybdenum-99, theraw material for technetium. Nordion, of Kanata, Ontario,
Radioisotope producer Nordion International has settled a disputewith a Canadian government agency that had stalled the constructionof nuclear reactors dedicated to producing molybdenum-99, theraw material for technetium. Nordion, of Kanata, Ontario, announcedlast week that it has signed a 20-year agreement with Atomic Energyof Canada Ltd. to fund the construction of two new reactors atAECL's Chalk River facility.
AECL supplies Nordion with molybdenum-99, which Nordion refinesand distributes to radiopharmaceutical customers, who use it tocreate technetium generators. AECL several years ago began buildinga new reactor as a backup to its existing National Research Universalfacility, which provides over 80% of the world's supply of molybdenum.AECL stopped work on the project in 1993, however, in a disputewith Nordion over the terms of a contract that stipulates howmuch AECL should be paid for its radioisotopes (SCAN 6/7/95 and11/17/93).
Last week's agreement resolved the dispute and should enablenuclear medicine practitioners to sleep easier. The first of AECL'stwo identical Maple reactors will begin operations in 1999, withthe second reactor scheduled to go online a year later. The NRUfacility will be decommissioned once the Maple reactors are completed.
The project will cost $140 million, with $100 million financedby an interest-free loan from the Canadian government. Nordionhas said that it will probably have to raise the price of molybdenumto pay for the project, an eventuality that most in the nuclearmedicine community have accepted in exchange for a stable supplyof technetium (SCAN 1/17/96).
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.